Table 8.

Relevant pharmacogenetics association studies that focused on serotonin receptor 2A (5HT2A)

Reference	Gene	Drug	Sample	Outcome measure	Results	p-value
[50]	5HT2A	Paroxetine	166 unipolar depressed patients	HAMD	HTR2A C(1354)T polymorphism showed an association with remission and response	p = 0.002 p = 0.01
[90]	5HT2A	Citalopram	1953 depressed patients (STAR*D)	HAMD	Positive association with a marker in the 5HT2A gene	p range 1 × 10-6 to 3.7 × 10-5
[48]	5HT2A	Fluoxetine	96 subjects with unipolar major depression	HAMD	Positive association with three markers in the 5HT2A gene	p = 0.001-0.03
[91]	5HT2A	Paroxetine, mirtazapine	246 elderly patients with major depression	Discontinuation rates	The presence and the severity of paroxetine-induced side effects were strongly associated with the T(102)C C/C genotype	p = 0.001
[60]	5HT2A	Fluvoxamine, paroxetine	248 bipolar and 195 depressed patients	HAMD	Marginal association between with theT(102)C C allele and the antidepressant response	p = 0.001
[76]	5HT2A	Various antidepressants	173 patients with major depression and 121 healthy controls	HAMD	Association between T(102)C C allele and antidepressant response	p = 0.023
[66]	5HT2A	Fluoxetine and paroxetine	100 depressed patients	HAMD	HTR2A: -1438G/G associated with a good response and with nausea in paroxetine-treated patients	p = 0.010 p = 0.013

Abbreviation: HAMD, Hamilton Rating Scale for Depression